Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Mersana Therapeutics completes $75 million IPO

By , Globe Staff

Seven-year-old Cambridge biotech starts trading on the Nasdaq exchange.

Roche to cut about 75 jobs in Marlborough

By , Globe Staff

Swiss drug giant says it’s part of the consolidation of its research and development operations.

SEC charges three with insider trading of Ariad stock

By , Globe Staff

The former Cambridge biotech company was acquired earlier this year by Japan’s Takeda.

Repligen agrees to buy Spectrum for $359 million

By , Globe Staff

Waltham life sciences company Repligen Corp. said it agreed to pay $359 million to acquire Spectrum Laboratories Inc.